Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs). more about the key technologies and tools used by Evonetix and how they Earlier this month, the Cambridge-based company said it has shown feasibility for the proprietary technology, which relies on selectively heating or . lorna.cuddon@zymecommunications.com, https://www.businesswire.com/news/home/20220816005493/en/. Michael Daniels joined Evonetix in March 2021 and brings over 20 years experience of marketing, product management and business development across the biotechnology sector. Mammen joined Cambridge Consultants as Chief Financial Officer in 2005. Matthew specialises in multi-disciplinary system design, medical device development, ASIC design and opto-electronics. Jim Tananbaum is the founder and chief executive officer of Foresite Capital, a U.S.-focused healthcare investment firm founded in 2011 that has $3 billion in assets under management. Operator of a biotechnology company intended to synthesize DNA at higher accuracy and scale. Prior to that, Raquel was a post-doctoral researcher in the Department of Chemical Engineering and Biotechnology, University of Cambridge, in the area of cancer gene therapy. Request an Annual Quote. C - 1, G - Block Bandra-Kurla Complex, Bandra (East) Mumbai 400 051. National Stock Exchange of India Limited Exchange Plaza, Plot No. Evonetix General Information. As a part of the partnership, Zaptic, and Molten Ventures will work together to scale the formers solution to help 700 million industrial workers across global supply chains, to operate flawlessly. The company develops a DNA and RNA synthesizer for molecular biology research purposes. Cambridge, England, United Kingdom. He works across a broad range of sectors from telecommunications to consumer products, focusing on the impact of digital platforms to enable new business models. Explore 47 technologies across 13 categories used by In 40 year career as an entrepreneur and venture capitalist, Hermann has helped start a number of technology companies, including Acorn Computers and its spin-out ARM, as well as Cambridge Silicon Radio and next-generation DNA sequencing technology company Solexa, which became the market leader and was later acquired by Illumina. The technical storage or access that is used exclusively for anonymous statistical purposes. PitchBooks comparison feature gives you a side-by-side look at key metrics for similar companies. Dr. Vishal Gulati is one of the Europes leading digital healthcare investors. Interview with Dr Matthew Hayes, Chief Technology Officer, Team Talk Daniel Bygrave, Group Head of Software, Evonetix closes $24 million USD (20 million) financing. It leverages semiconductor-controlled synthesis on silicon which enables ultra-parallel DNA preparation, and moving capacity from remote service centers. The investment round was led by London VC Molten Ventures that recently backed Evonetix and Hadean , with participation from existing investors. Companies that are using technology to make farms more efficient. Distinguished as a science-based innovator and serial-entrepreneur Hermanns ventures have been at the forefront of UK innovation. Providence Investment Company is the family office of Hermann Hauser and, together with Cambridge Consultants, is the founding investor of Evonetix. Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions. lorna.cuddon@zymecommunications.com, Internet Explorer presents a security risk. Instead, shift your stock portfolio . Combined with the Companys patented chemistry, this approach enables the accurate synthesis of thousands of sequences on a single chip to meet the demand for complex libraries and assembly of long DNA, addressing the DNA supply bottleneck in the field of synthetic biology. Malcolm joined Evonetix in June 2021 with over 20 years of experience. Get instant access to B2B contact data across the web, We use cookies to improve your browsing experience. Professor Andrew Briggs is Professor of Nanomaterials at the University of Oxford, where his research focuses on materials and techniques for quantum information technologies and investigating vibrational states of nanotubes and charge transport through single molecules in graphene nanogaps. This investment will support us as we execute on our commercial strategy to put benchtop gene synthesis in the hands of users. The Company develops technology that enables the parallel synthesis of DNA on silicon arrays. You can read more about your cookie choices at our privacy policyhere. Sources. Mammen graduated with a first class degree in Commerce from the University of Madras, India. Civilization Ventures leverages an extensive network of world-class scientists and clinicians (including half a dozen MDs and PhDs), as well as accomplished founders and CEOs from our portfolio companies, to gain access to and understand the leading innovations in our space. This fundraise was led by existing investor Foresite Capital, with Molten Ventures, Morningside, DCVC, Cambridge Consultants, Civilization Ventures and Providence also participating in the round. Get the full list, Youre viewing 5 of 10 board members. Determine how Evonetix's purchase behavior is going to change over the next few weeks. Before these roles, Malcolm had over 15 years experience in professional services with PwC. Evonetixs DNA synthesis capability brings together patented semiconductor chip design and proprietary, thermally controlled synthesis chemistry, which will be integral to the Companys future gene synthesis platforms. As CEO of Evonetix, Colin will focus on building strategic partnerships and customer relationships, ahead of the commercial introduction of the Companys first benchtop DNA printer. Jason Pontin is a Partner at DCVC, where his belief that emerging technologies and new scientific insights can solve urgent challenges and expand human possibilities inspires his investments in Deep Tech and life sciences companies. Farfetch (NYSE: FTCH) is a specialized player in luxury fashion . At TED 2013, he delivered a Talk, Can technology solve our big problems? which has been seen 1.6 million times. At MIT, he founded MIT Solve, the Institutes open innovation platform, which deploys capital and other resources toward solutions to grand challenges; chaired the MIT Enterprise Forum, the Institutes global entrepreneurial community; and was senior advisor to MITs 16th President, Susan Hockfield. Let's dig . Paul Beastall is the Head of Strategy and member of the senior leadership team at Cambridge Consultants. You can read more about your cookie choices at our privacy policyhere. Check the background of this firm on FINRAs BrokerCheck. Developer of instrumentation for gene synthesis analysis. Ulta Beauty (NASDAQ: ULTA), which sells cosmetics, seems to have defied this paradigm. Blood stem cell company Garuda Therapeutics Inc. has raised $62 million in a series B round led by Northpond Ventures, OrbiMed Advisors, Cormorant Asset Management and Aisling Capital. Zyme Communications What challenge does Zaptic solve? Researchers are invited to apply to be included in the Companys early access program to receive some of the first DNA prepared using its technology and demonstrate the efficacy of Evonetix DNA in routine molecular biology workflows. He has delivered commercial success in numerous leadership positions, including Vice President and General Manager and Vice President of Sales at Thermo Fisher Scientific, Vice President and Head of European Sales at Life Technologies and National Sales Manager at Qiagen. Microsoft Azure Malcolm joined Evonetix in June 2021 with over 20 years of experience. Evonetix has 10 investors. evonetix is seeking to develop and commercialise a new approach to the synthesis of DNA. Among his operational responsibilities at DCVC, he helps portfolio companies tell their stories. Raquel holds a PhD in Molecular and Cell Biology from the Faculty of Medicine, University of Auvergne and a MSci in Biochemistry from the Faculty of Sciences, University of Lisbon. Over the last decade he has championed deals across areas including diagnostics, devices & biotech. Civilization Ventures is a venture capital firm focused on cutting edge innovations in exponential health tech and biology that address key opportunities in rapidly growing markets. He has delivered commercial success in numerous leadership positions, including Vice President and General Manager and Vice President of Sales at Thermo Fisher Scientific, Vice President and Head of European Sales at Life Technologies and National Sales Manager at Qiagen. GeneDx to Execute 1-for-33 Reverse Stock Split Illumina to Taper Annual Spending by $100M; Q1 Revenues . Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. Cambridge. Analyst Briefing Submitters are 7x more likely to receive a qualified connection. His previous roles include Director level positions in Marketing and Product Management at Thermo Fisher Scientific and Arcis Biotechnology, leadership of the Cell and Molecular Research Tools business segment at GE Healthcare and head of Marketing & Business Development at Promega UK. Revenue. The company aims to create a benchtop instrument that . Molecular Assemblies develops an enzymatic DNA synthesis technology designed to power DNA-based products. All rights reserved. He primarily operated from a base in Singapore. Use this section to learn Jason was CEO and editor in chief of MIT Technology Review and editor of Red Herring magazine, the bible of the dot.com boom. We use cookies to optimise our website and our service. Our desktop DNA synthesis platform will provide the ability to synthesise DNA at unprecedented accuracy, scale and speed, accelerating scientists' ability to use biology on a scale not currently possible. Address. Jim Tananbaum is the founder and chief executive officer of Foresite Capital, a U.S.-focused healthcare investment firm founded in 2011 that has $3 billion in assets under management. JavaScript Evonetix's headquarters is located at 9A Coldhams Business Park, Norman Way, Cambridge. Finance. Evonetix Closes $24 Million USD (20 Million) Financing CAMBRIDGE, England--(BUSINESS WIRE)--EVONETIX LTD ('Evonetix'), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced it has completed a USD $24 million financing round, extending its total series B funding to over USD $54 million (circa GB 44 million). Hermann Hauser, entrepreneur and co-founder of Amadeus Capital Partners, supported the foundation of Evonetix in 2015, together with Cambridge Consultants. In addition to this, the company will use the investment to develop its no-code platform that will help manufacturers bridge the existing skills gap and digitise daily operations in such a way that it closes the data loop and brings in the use of AI in factories. Error detection during hybridisation of target double-stranded nucleic acid, UK-based Zaptic raises $10M to develop connected platform for frontline workers, SynBioBeta's Reading, Writing & Editing DNA Digest, The enzymatic DNA synthesis market is expected to grow from US$ 240.96 million in 2022 to US$ 2,244.88 million by 2028; it is estimated to record a CAGR of 45.1% from 2022 to 2028, Enzymatic DNA Synthesis Market Worth $2.24 Billion, by 2028 with 45.1% CAGR Global Report by The Insight Partners, Gene Synthesis Market Size, Share & Trends Analysis Report By Method, By Service, By Application, By End-use, By Region And Segment Forecasts, 2023 - 2030. CBI websites generally use certain cookies to enable better interactions with our sites and services. Foresite Capital understands the unique business models in healthcare and works closely with the firms portfolio companies at all stages of their lifecycle. Matt holds a Masters degree in Mechanical Engineering from the University of Durham and is a Chartered Member of the Institution of Mechanical Engineers. affect the user interaction and engagement with the company. Trevor has a BSc in Computer Programming and Chemistry from Anglia Ruskin University. Our engineering team has decades of experience developing high integrity automated systems. Evonetix develops a desktop, short-latency solution to synthesize DNA to facilitate the field of synthetic biology, with applications across industries including healthcare, pharma, biotech, food and agriculture, and data storage. See more The 3 most popular patent topics include: Molecular biology, Error detection and correction, Genetics, Biotechnology, DNA. The group is managed by investment professionals who are entrepreneurial, have deep industry knowledge and are effective in the local environment in which they operate. Before these roles, Malcolm had over 15 years experience in professional services with PwC. Jim assembles the people, ideas and money needed to launch products that save lives and improve healthcare. About evonetix Stock. Ut enim ad minim veniam, aliquip ex ea commodo consequat. In addition to publishing nearly 600 peer-reviewed scientific papers, he is the author of several books that address scientific issues in the context of a broader humanist debate. Find useful insights on Evonetix Ltd's company details, tech stack, news alerts, competitors and more. You can read more about your. He focussed on Programme and Line Management in the UK before taking a secondment to the US to lead the expansion of the Boston site into Industrial and Consumer. All trademarks are the property of Evonetix Ltd. or their respective owners. Evonetix is in the industry of Building a platform capable of this requires highly parallel, distributed synthesis. His research focuses on developing quantitative biophysical methods, applied to biology and biomedicine. you agree to our privacy policy. and M.A in humanities fields completely unrelated to his investment interests. Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. Colin brings over 20 years experience in commercial and business development roles. These roles have given Malcolm experience of developing companies as they grow in size and complexity. The firm seeks to address areas of great unmet medical need by funding and supporting transformative healthcare businesses. Yen Bulls Are Pushing Back Bets on BOJ Tailwind to the Summer, Hedge Funds Bet Dollar to Erase Hike-Cycle Gains as Fed Peaks, How Much ECB Hikes This Week Hinges on One Data-Packed Morning, Korean Export Falls Ease in Possible Sign of Stabilizing Demand, Chinas Mixed Economic Data Fuels Concerns About Recovery, Softbanks Arm Says It Registered Confidentially for US IPO, Bank Failures, Broken Markets Loom Over Milkens Capitalist Utopia, Pitched Fight for Stock Market Supremacy Was Masked by VIXs April Plunge, AI Chatbots Have BeenUsed to Create Dozens of News Content Farms, SoftBank Shares Rise After Arm Files Confidentially for IPO, Eastern Europe Is Jeopardizing anEconomic Lifeline for Ukraine, France Braces for Renewed Anti-Macron Protests on Labor Day, Peter Thiel Tells Black-Tie NYC Audience That Diversity Is a Distraction, What You Need to Know About the Biden Administrations New Mortgage Fees, Russias Most Famous Fashion Designer, Who Dressed First Ladies, Dies at 85, Pope voices willingness to return Indigenous loot, artifacts, The Slow Dance Between Markets and Central Banks, The Oil Industrys Unhappy Marriage Is Starting To Face Facts, Dont Make It Too Hard for Americans to Investin China, The Boring Old Box Truck Gets the Tesla Treatment, For Banks Under Stress, Theres a Federal Backstop That Provides Help Without Stigma, What the US Can Learn From Europes ESG Mistakes, Japan Coalition Party Says More Handouts for Kids Top Priority, Scrapping Housing Targets Will Cost Renters 200 a Year, Says Labour, What to Know About Red-Flag Warnings, an Ominous WildfireForecast, Occidental Hopes to Sell the Carbon It Capturesat the Worlds Biggest Plant, Germany Sets the New Standard for Cheap, National Mass Transit, Chinas Now Spurning Ugliest Buildings That Symbolized Its Meteoric Rise, Broke Chinese Gen Zs Turn Factory Town into Top Tourist Spot, Bitcoin Sags After its Longest Streak of Monthly Gains Since 2021, Bitcoin on Course for Longest Streak of Monthly Gains Since 2021, Cross River Bank Gets FDIC Enforcement Order Over Lending. You can find more about their employees through LinkedIn or their website using Professor Andrew Briggs is Professor of Nanomaterials at the University of Oxford, where his research focuses on materials and techniques for quantum information technologies and investigating vibrational states of nanotubes and charge transport through single molecules in graphene nanogaps. Enzymatic DNA synthesis can write long, pure DNA, which is required to free the potential of synthetic biology applications, such as personalized medicines (including CAR-T cell therapies and CRISPR gene editing) and advanced agricultural and industrial products, through gene development and DNA-based data storage. Evonetix is a growing biotechnology company which is set to revolutionisegene synthesis as needed to facilitate the View all He holds a PhD and MEng in Electronic Engineering, both from Loughborough University. 13 categories used by Evonetix mentioned earlier on this page. By accessing this site and any pages thereof, you agree to be bound by our Terms of Use.EquityZen and logo are trademarks of EquityZen Inc. Other trademarks are property of their respective owners. 2023 EquityZen Inc. All rights reserved. CBI websites generally use certain cookies to enable better interactions with our sites and services. Before joining Evonetix, Raquel was at Solexa (then Illumina Inc.) from 2002 as a Protein Engineer and major contributor to its disruptive NGS technology. As a collegial partnership with diverse areas of expertise, they seek to team with and help accelerate the growth of visionary companies breaking barriers and innovating in new markets, especially those creating or leveraging technological advancements in Cloud, Data, Artificial Intelligence, Life Sciences & Health, Mobility, Automation & Robotics, Financial Technology, Security, Blockchain, and Mixed Reality. Evonetix brings together the talents of an astonishing group of scientists and engineers, across biology, physics, electronics, chemistry, software and mechanics; all with the same mission, to unlock the capabilities of semiconductor technology for the world of synthetic biology. Matt Hayes, Founder and Chief Technology Officer at Evonetix, said: We have been working on optimising the different elements of our technology ready to share DNA with researchers. : Outcome of the Board Meeting held on April 29, 2023. Before joining Evonetix, Raquel was at Solexa (then Illumina Inc.) from 2002 as a Protein Engineer and major contributor to its disruptive NGS technology. Operator of a biotechnology company intended to synthesize DNA at higher accuracy and scale. Investors. Trevor Joined Evonetix as COO in January 2023 with over 23 years experience in the semiconductor industry. September 09, 2020 08:00 AM Eastern Daylight Time. A major contributor to the global technology and growth agendas . This investment from Molten Ventures will allow us to scale our business to meet that demand and continue to invest deeply into creating an operational knowledge layer for workers, with operational data enabled by AI. His investments include Napo Pharmaceuticals, Glenmark, Renovo, Phagenesis. The company's platform plac. Developer of instrumentation for gene synthesis analysis. The current model for DNA synthesis cant deliver on the future demand for DNA. Hermann Hauser, entrepreneur and co-founder of Amadeus Capital Partners, supported the foundation of Evonetix in 2015, together with Cambridge Consultants. This year, DNA Day celebrates 70 years since James Watson and Francis Crick discovere t.co/7mzJmfskJg, Evonetix Ltd He is always looking for visionaries: men and women with insights into therapeutics, devices, diagnostics or services that could, with the right support, change the world. Prior to joining Evonetix he was Senior Vice President and Chief Commercial Officer at Fluidigm Corp, where he was responsible for leading all commercial activities, driving revenue growth, and expanding the Companys global reach. See our privacy policy for more information regarding 6senses It not only unlocks measurable improvements in productivity, quality and safety but also enables a smooth transfer of knowledge between the retiring and new generation of workers to improve market resiliency. Iridia is developing a DNA-based data storage solution.